Aptose Biosciences Inc (TSE:APS)‘s stock had its “outperform” rating reissued by analysts at Royal Bank Of Canada in a report issued on Friday, StockTargetPrices.com reports. They currently have a C$24.00 price objective on the stock.
Shares of Aptose Biosciences (TSE:APS) opened at 2.85 on Friday. The firm has a 50-day moving average of $2.91 and a 200 day moving average of $3.19. The company’s market capitalization is $36.74 million. Aptose Biosciences has a 52-week low of $2.51 and a 52-week high of $8.33.
Aptose Biosciences Company Profile
Aptose Biosciences Inc (Aptose) is a clinical-stage biotechnology company. The Company is engaged in the development of anticancer drugs that target specific epigenetic processes and signal transduction abnormalities that underlie a particular life-threatening malignancy. Its product pipeline includes cancer drug candidates that exert activity as stand-alone agents and that enhance the activities of other anticancer agents without causing overlapping toxicities.
Receive News & Ratings for Aptose Biosciences Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences Inc and related companies with MarketBeat.com's FREE daily email newsletter.